New drug targets advanced cancers in the brain
NCT ID NCT05865990
Summary
This study is testing an experimental drug called HER3-DXd for patients whose breast cancer, lung cancer, or other solid tumors have spread to the brain or the lining around the brain. The goal is to see if the drug can shrink these hard-to-treat brain tumors and help patients live longer. About 63 participants will receive the drug by IV infusion every three weeks until their cancer worsens or side effects become too severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital Arnau de Vilanova de Valencia
Valencia, Spain
-
Hospital Beata María Ana
Madrid, Spain
-
Hospital Quirónsalud Sagrado Corazón
Seville, Spain
-
Hospital Universitari Dexeus
Barcelona, Spain
-
Hospital Universitari Vall D'Hebron
Barcelona, Spain
-
Hospital Universitario Virgen del Rocío
Seville, Spain
-
Medical University of Vienna
Vienna, Austria
-
Salzburg Cancer research Institute-Center for Clinical Cancer and Immunology Trials
Salzburg, Austria
Conditions
Explore the condition pages connected to this study.